Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 217

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 5
Chunk 217
---
eneron, is ongoing at a relatively minimal cost to BioLineRx. We expect this
program to continue to advance without any significant expense to us.

A key component of our strategy moving forward is to in-license
additional assets in oncology and/or rare diseases that exhibit distinct advantages over currently available therapies or address unmet
medical needs that we can advance through clinical development. We have generated our pipeline by systematically identifying, rigorously
validating and in-licensing therapeutic candidates that we believe exhibit a high probability of therapeutic and commercial success. We
have substantial experience in scouting and assessing assets in transactions with back-ended, success-based consideration, which can be
acquired or licensed for a modest upfront payment, and with relatively modest and affordable clinical development programs. We are actively
working on this initiative and are being presented with many promising opportunities that meet these criteria.

60

Our longer-term vision is to develop innovative assets with significant
potential value whose development costs have been offset by the royalties and milestones from our existing motixafortide partnerships.
We aim to continue pursuing new partnerships on these programs to create additional value for our shareholders.